K. Park

1.2k total citations
54 papers, 781 citations indexed

About

K. Park is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, K. Park has authored 54 papers receiving a total of 781 indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 45 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in K. Park's work include Lung Cancer Treatments and Mutations (40 papers), Colorectal Cancer Treatments and Studies (20 papers) and Lung Cancer Research Studies (13 papers). K. Park is often cited by papers focused on Lung Cancer Treatments and Mutations (40 papers), Colorectal Cancer Treatments and Studies (20 papers) and Lung Cancer Research Studies (13 papers). K. Park collaborates with scholars based in South Korea, United States and Spain. K. Park's co-authors include Yi‐Long Wu, P. Gopalakrishna, Bruno Coudert, Dariusz M. Kowalski, Kihyun Kım, Wolfram Brugger, Giuseppe Giaccone, Tudor–Eliade Ciuleanu, Federico Cappuzzo and Baek‐Yeol Ryoo and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

K. Park

50 papers receiving 769 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
K. Park South Korea 14 560 448 146 84 81 54 781
Donald Woytowitz United States 11 477 0.9× 397 0.9× 172 1.2× 36 0.4× 146 1.8× 19 731
Suchita Pakkala United States 15 685 1.2× 522 1.2× 154 1.1× 106 1.3× 120 1.5× 32 973
Jean Pierre Delord France 13 514 0.9× 185 0.4× 233 1.6× 64 0.8× 90 1.1× 20 792
M. Puglisi Italy 16 539 1.0× 408 0.9× 257 1.8× 111 1.3× 90 1.1× 38 998
N. J. Vogelzang United States 16 302 0.5× 290 0.6× 286 2.0× 41 0.5× 82 1.0× 38 759
Charles Ricordel France 14 467 0.8× 529 1.2× 198 1.4× 40 0.5× 36 0.4× 74 787
Stéfano Kim France 18 447 0.8× 293 0.7× 161 1.1× 72 0.9× 57 0.7× 74 827
Livia L. Szeto United States 11 346 0.6× 284 0.6× 236 1.6× 66 0.8× 35 0.4× 32 584
Reury-Perng Perng Taiwan 20 598 1.1× 748 1.7× 164 1.1× 143 1.7× 152 1.9× 51 1.1k
J.J. Lafitte France 13 504 0.9× 481 1.1× 296 2.0× 126 1.5× 23 0.3× 39 930

Countries citing papers authored by K. Park

Since Specialization
Citations

This map shows the geographic impact of K. Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by K. Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites K. Park more than expected).

Fields of papers citing papers by K. Park

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by K. Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by K. Park. The network helps show where K. Park may publish in the future.

Co-authorship network of co-authors of K. Park

This figure shows the co-authorship network connecting the top 25 collaborators of K. Park. A scholar is included among the top collaborators of K. Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with K. Park. K. Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Rodríguez‐Abreu, Delvys, Martin Reck, K. Park, et al.. (2022). 6MO Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up. Annals of Oncology. 33. S30–S31. 2 indexed citations
2.
Shu, Catherine A., Keiko Goto, Yuichiro Ohe, et al.. (2021). 1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2. Annals of Oncology. 32. S952–S953. 13 indexed citations
3.
Gautschi, Oliver, Alexander Drilon, Daniel S.W. Tan, et al.. (2020). 1290P Efficacy and safety with selpercatinib by last prior systemic therapy received in patients (Pts) with RET fusion + non-small cell lung cancer (NSCLC). Annals of Oncology. 31. S835–S835. 1 indexed citations
4.
McCoach, Caroline E., Benjamin Besse, Keiko Goto, et al.. (2020). 1291P Hypersensitivity reactions (HR) to selpercatinib in RET fusion+ non-small cell lung cancer (NSCLC) patients (pts) following immune checkpoint inhibition (CPI). Annals of Oncology. 31. S835–S836. 6 indexed citations
5.
Kim, Dongwook, Ullas Batra, K. Park, et al.. (2020). 1348P Efficacy and safety of ceritinib 450 mg-fed vs 750 mg-fasted in Asian patients (pts) with ALK+ non-small cell lung cancer (NSCLC) in the ASCEND-8 trial. Annals of Oncology. 31. S864–S865. 1 indexed citations
6.
7.
Wu, Yi‐Long, Ying Cheng, Jianfeng Zhou, et al.. (2019). MA09.09 Long-Term Outcomes to Tepotinib Plus Gefitinib in Patients with EGFR-Mutant NSCLC and MET Dysregulation: 18-Month Follow-Up. Journal of Thoracic Oncology. 14(10). S284–S284. 7 indexed citations
8.
Riely, Greg J., et al.. (2018). P1.01-81 Phase 3 Study of Pemetrexed-Platinum with or without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789. Journal of Thoracic Oncology. 13(10). S494–S494. 18 indexed citations
9.
Paz-Ares, L., David Planchard, James Chih‐Hsin Yang, et al.. (2018). MA26.10 CNS Activity of Ramucirumab in Combination with Osimertinib in Patients with Advanced T790M-Positive EGFR-Mutant NSCLC. Journal of Thoracic Oncology. 13(10). S453–S454. 2 indexed citations
10.
Socinski, Mark A., Mustafa Özgüroğlu, Ana Villegas, et al.. (2018). P1.16-04 Outcomes of Patients <70 or ≥70 Years of Age in PACIFIC. Journal of Thoracic Oncology. 13(10). S628–S629. 2 indexed citations
11.
12.
Schüler, Martin, Luis Paz‐Ares, Lecia V. Sequist, et al.. (2017). First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders (LTRs) in the LUX-Lung (LL) 3, 6 and 7 trials. Annals of Oncology. 28. ii33–ii33. 2 indexed citations
13.
Park, K., Fortunato Ciardiello, Toyoaki Hida, et al.. (2017). Phase I/II study of S 49076, a MET/AXL/FGFR inhibitor, in combination with gefitinib in EGFR-mutated NSCLC patients who progress on EGFR tyrosine kinase inhibitor. Annals of Oncology. 28. v493–v493. 4 indexed citations
14.
Barlési, Fabrice, K. Park, Fortunato Ciardiello, et al.. (2016). Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. Annals of Oncology. 27. vi581–vi581. 56 indexed citations
15.
16.
Tan, Daniel S.W., et al.. (2015). 479TiP Phase Ib trial of afatinib and BI 836845 in advanced non-small cell lung cancer (NSCLC). Annals of Oncology. 26. ix125–ix125.
17.
18.
Kubota, Kaoru, Y. Ichinose, Giorgio V. Scagliotti, et al.. (2014). Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous nonsmall-cell lung cancer (NSCLC): Asian subgroup analysis. Annals of Oncology. 25(2). 529–536. 20 indexed citations
19.
Pirker, Robert, J. R. Pereira, Aleksandra Szczęsna, et al.. (2012). Prognostic factors in patients with advanced non-small cell lung cancer: Data from the phase III FLEX study. Lung Cancer. 77(2). 376–382. 5 indexed citations
20.
Lee, D.H., Cheolwon Suh, Jeong Hyun Lee, et al.. (2007). Belotecan, new camptothecin analogue, is active in patients with small-cell lung cancer: results of a multicenter early phase II study. Annals of Oncology. 19(1). 123–127. 42 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Donald Woytowitz Breakdown of academic impact, for papers by Suchita Pakkala Breakdown of academic impact, for papers by Jean Pierre Delord Breakdown of academic impact, for papers by M. Puglisi Breakdown of academic impact, for papers by N. J. Vogelzang Breakdown of academic impact, for papers by Charles Ricordel Breakdown of academic impact, for papers by Stéfano Kim Breakdown of academic impact, for papers by Livia L. Szeto Breakdown of academic impact, for papers by Reury-Perng Perng Breakdown of academic impact, for papers by J.J. Lafitte
Rankless by CCL
2026